Special Issue

Combined CAR T-cell Therapies: A Next Step towards Precision Oncology

Message from the Guest Editor

Chimeric antigen receptor (CAR) T cell therapy is a rapidly growing field with unparalleled clinical success rates for the treatment of patients with relapsed or refractory B cell malignancies. However, translation toward other tumor entities is still limited as CAR T-cells alone might not be sufficient to elicit durable responses. Reasons are multifaceted and include, e.g., the lack of true tumor-specific markers, the immunosuppressive tumor microenvironment, tumor heterogeneity, and the selection and induction of therapy-resistant tumor cell clones or previous treatment modalities. To overcome these hurdles and to boost CAR T-cell cytotoxicity, various combinatorial or multiple tumor targeting approaches are intensively investigated, but combinations with other treatment modalities, such as standard chemo- or radiotherapy, small molecule inhibitors or targeted therapies, also play an increasingly important role. This Special Issue aims to cover recent advances in combined CAR T-cell approaches as well as new imaging methods and therefore seeks for review or original manuscripts addressing one of the aforementioned (or related) topics.

Guest Editor

Dr. Claudia Arndt

1. HZDR - Helmholtz-Zentrum Dresden-Rossendorf, Institute of Radiopharmaceutical Cancer Research Dresden, Dresden, Germany
2. Mildred Scheel Early Career Center, Faculty of Medicine Carl Gustav Carus, TU Dresden, Dresden, Germany

Deadline for manuscript submissions

closed (31 October 2022)

Cancers

an Open Access Journal by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed

mdpi.com/si/82697

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

mdpi.com/journal/cancers

Cancers

an Open Access Journal by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed

mdpi.com/journal/cancers

MDPI

About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok
Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)